Literature DB >> 3043116

Cognition activators.

W H Moos1, R E Davis, R D Schwarz, E R Gamzu.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3043116     DOI： 10.1002/med.2610080303

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


× No keyword cloud information.
  8 in total

1.  The utility of muscarinic agonists in the treatment of Alzheimer's disease.

Authors:  William S Messer
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices.

Authors:  A M Pugliese; R Corradetti; L Ballerini; G Pepeu
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 4.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Effect of a new nootropic agent, CGS 5649B, on cognition, function, and behavior in dementia.

Authors:  D W Molloy; G H Guyatt; T Standish; A Willan; W McIlroy; J D'Souza; G Brown; C Mondadori
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

Review 6.  Development of pharmacological treatments for Alzheimer-type dementia.

Authors:  J Cornwall; T H Corn
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

7.  Synthesis of 2-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8-azabicyclo [3.2.1]octanes and 2 alpha-(3-substituted-1,2,4-oxadiazol-5-yl)-8-methyl-8- azabicyclo[3.2.1]oct-2-enes as potential muscarinic agonists.

Authors:  D J Triggle; Y W Kwon; P Abraham; M A Rahman; F I Carroll
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

8.  PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.

Authors:  M R Emmerling; V E Gregor; R D Schwarz; J D Scholten; M J Callahan; C Lee; C J Moore; C Raby; W J Lipinski; R E Davis
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.